СПЕЦИФИЧЕСКИЙ ИММУННЫЙ ОТВЕТ К ОТДЕЛЬНЫМ КАПСУЛЬНЫМ ПОЛИСАХАРИДАМ STREPTOCOCCUS PNEUMONIAE У ЗДОРОВЫХ ДОНОРОВ КРОВИ И ЛИЦ, ИММУНИЗИРОВАННЫХ ПНЕВМОКОККОВЫМИ ВАКЦИНАМИ

Aim. Evaluate humoral immune IgG response to 13 specific capsule polysaccharides in healthy blood donors and individuals immunized with pneumococcal vaccines. Materials and methods. A solid-phase EIA method was used with sorption on polystyrol of pneumococcal CPS isolated by us (1, 3, 4, 6A, 6B, 7F, 9N, 9V, 14, 18C, 19A, 19F, 23F). Blood sera of 140 healthy donors, 42 conscripts (young males) vaccinated with Pneumo-23 and 5 adults that are frequently ill with various bronchial-lung diseases for a long time and vaccinated with Prevenar-13 preparation were analyzed. IgG level was expressed in conventional units. Results. The mean level of antibodies against pneumococcal CPS in donors was at the level of 70 c.u.; in conscripts during the prevaccination period - 50 c.u.; in frequently ill for a long time - 90 c.u. In 14 of140 donors increased antibody levels against one or several CPS simultaneously were observed. During post-vaccinal period in vaccinated with Pneumo-23 an increase of antibody levels against 12 - 13 CPS varying by specificity was observed only in 9 of 42 individuals; 1 individual did not have an increase of antibody levels against any of the 13 CPS; in 32 of 42 - the antibody levels against 1 or several CPS did not increase. In 5 individuals vaccinated with Prevenar-13 a rise of antibody levels against 1 - 9 CPS, that are included in the vaccine, was not detected. Conclusion. Thus, clinical trials during registration of newly developed vaccines should, in our opinion, include evaluation of the initial levels of specific antibodies against each polysaccharide component of the vaccine in blood sera of all groups of volunteers. This would allow to evaluate the effectiveness of the vaccination.